Banner for leaf pages 2

Etravirine (Intelence)

Also known as Intelence

Etravirine (ETR, brand name Intelence, formerly known as TMC125) is a drug used for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Etravirine works by reducing the amount of HIV and increasing the number of CD4 or T cells in the blood. Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine. Etravirine is marketed by Tibotec, a subsidiary of Johnson & Johnson. In January 2008, the Food and Drug Administration approved its use for patients with established resistance to other drugs, making it the 30th anti-HIV drug approved in the United States and the first to be approved in 2008. It was also approved for use in Canada on April 1, 2008.

Source: Wikipedia

Estimated Total Cost: $705.65 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed etravirine to treat human immunodeficiency virus infection (hiv), viral hepatitis, blastomycosis, and rabies.

What side effects are related?

Patients taking etravirine most commonly experience side effects like skin rash and peripheral nerve disorder.

Ajax-loader Loading...